Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors

Clinical Neuropathology

Volumn 27, Issue 4, 2008, Pages 219-223

  Donato, Giuseppe ^a,d   Iofrida, G ^a   Lavano, A ^a   Volpentesta, G ^a   Signorelli, F ^a   Pallante, P L ^b   Berlingieri, M T ^b   Pierantoni, M G ^b   Palmieri, D ^b   Conforti, F ^a   Maltese, L ^a   Tucci, L ^c   Amorosi, A ^a   Fusco, A ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d Policlinico Mater Domini   (Italy)

Author keywords

Astrocytic tumors; Gliosis; Immunohistochemistry; Proteasome inhibitors; UbcH10

Indexed keywords

PROTEASOME INHIBITOR; UBIQUITIN CONJUGATING ENZYME;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; GENE REPRESSION; GLIOBLASTOMA; GLIOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MARKER GENE; PRIORITY JOURNAL; TISSUE DIFFERENTIATION; UBCH10 GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-CONJUGATING ENZYMES;

EID: 47349114226     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27219     Document Type: Article

References (12)

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunoistochemical analysis. Mod Pathol. 1998; 11: 155-168.
2. Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 1990; 344: 503-508.
3. Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A, Barbareschi M, Ferro A, Troncone G, Fusco A. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2007; 26: 2136-2140.
4. Chen CC, Chang TW, Chen FM, Hou MF, Hung SY, Chong IW, Lee SC, Zhou TH, Lin SR. Combination of multiple mRNA markers (PTTG1, Survivin, UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array. Oncology. 2006; 70: 438-446.
5. Ciechanover A. The ubiquitin proteolytic system. From an idea to the patient bed. Proc Am Thorac Soc. 2006; 3: 21-31.
6. Fujita T, Doihara H, Washio K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs. 2006; 17: 455-462.
7. Kleihues P, Buerger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Pathology and Genetics of Tumours of the Central Nervous System. In: Kleihues P, Cavenee WK (eds). World Health Organization Classification of Tumours. Lyon: IARC Press; 2000. p. 6-69.
8. Lynch T Jr, Kim E. Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer. 2005; 2 (Suppl): S25-S32.
9. Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 1990; 344: 503-508.
10. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Palombini L, Fusco A. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005; 93: 464-471.
11. Piccaluga PP, Martinelli G, Baccarani M. Advances in the treatment for haematological malignancies. Exp Opin Pharmacother. 2006; 7: 721-732.
12. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux Q, Hampton GM. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004; 23: 6621-6629.